|
Oncogenes and Tumor Suppressors
Citations 351-360 of 795 total displayed.
|
Past content
(since May 2000):
|
Repressible transgenic model of NRAS oncogene–driven mast cell disease in the mouse
- Stephen M. Wiesner, Jamie M. Jones, Diane E. Hasz, and David A. Largaespada
Blood 2005; 106: 1054-1062.
[Abstract]
[Full text]
[PDF]
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
- Barbara Wassmann, Heike Pfeifer, Michael Stadler, Martin Bornhaüser, Gesine Bug, Urban J. Scheuring, Patrick Brück, Matthias Stelljes, Rainer Schwerdtfeger, Nadezda Basara, Jolanta Perz, Donald Bunjes, Georg Ledderose, Rolf Mahlberg, Anja Binckebanck, Harald Gschaidmeier, Dieter Hoelzer, and Oliver G. Ottmann
Blood 2005; 106: 458-463.
[Abstract]
[Full text]
[PDF]
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
- Mark Levis, Kathleen M. Murphy, Rosalyn Pham, Kyu-Tae Kim, Adam Stine, Li Li, Ian McNiece, B. Douglas Smith, and Donald Small
Blood 2005; 106: 673-680.
[Abstract]
[Full text]
[PDF]
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412
- Joseph D. Growney, Jennifer J. Clark, Jennifer Adelsperger, Richard Stone, Doriano Fabbro, James D. Griffin, and D. Gary Gilliland
Blood 2005; 106: 721-724.
[Abstract]
[Full text]
[PDF]
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit
- Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, III, Raji Sundaramoorthi, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David Dalgarno, John Iuliucci, Tomi K. Sawyer, Michael C. Heinrich, Brian J. Druker, and Michael W. N. Deininger
Blood 2005; 106: 227-234.
[Abstract]
[Full text]
[PDF]
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
- Chunaram Choudhary, Joachim Schwäble, Christian Brandts, Lara Tickenbrock, Bülent Sargin, Thomas Kindler, Thomas Fischer, Wolfgang E. Berdel, Carsten Müller-Tidow, and Hubert Serve
Blood 2005; 106: 265-273.
[Abstract]
[Full text]
[PDF]
NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia
- Ying-Wei Lin, Christopher Slape, Zhenhua Zhang, and Peter D. Aplan
Blood 2005; 106: 287-295.
[Abstract]
[Full text]
[PDF]
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
- Suzanne Schubbert, Kenneth Lieuw, Sara L. Rowe, Connie M. Lee, XiaXin Li, Mignon L. Loh, D. Wade Clapp, and Kevin M. Shannon
Blood 2005; 106: 311-317.
[Abstract]
[Full text]
[PDF]
Constitutively activated FGFR3 mutants signal through PLC -dependent and -independent pathways for hematopoietic transformation
- Jing Chen, Ifor R. Williams, Benjamin H. Lee, Nicole Duclos, Brian J. P. Huntly, Daniel J. Donoghue, and D. Gary Gilliland
Blood 2005; 106: 328-337.
[Abstract]
[Full text]
[PDF]
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
- Susan P. Whitman, Shujun Liu, Tamara Vukosavljevic, Laura J. Rush, Li Yu, Chunhui Liu, Marko I. Klisovic, Kati Maharry, Martin Guimond, Matthew P. Strout, Brian Becknell, Adrienne Dorrance, Rebecca B. Klisovic, Christoph Plass, Clara D. Bloomfield, Guido Marcucci, and Michael A. Caligiuri
Blood 2005; 106: 345-352.
[Abstract]
[Full text]
[PDF]
|
|
